Joint analysis of longitudinal measurements and survival data has received much attention in recent years. However, previous work has primarily focused on a single failure type for the event time. In this paper we consider joint modeling of repeated measurements and competing risks failure time data to allow for more than one distinct failure type in the survival endpoint which occurs frequently in clinical trials. Our model uses latent random variables and common covariates to link together the sub-models for the longitudinal measurements and competing risks failure time data, respectively. An EM-based algorithm is derived to obtain the parameter estimates, and a profile likelihood method is proposed to estimate their standard errors. Our method enables one to make joint inference on the multiple outcomes which is often necessary in analyses of clinical trials. Furthermore, joint analysis has several advantages compared with separate analysis of either the longitudinal data or competing risks survival data. By modeling the event time, the analysis of longitudinal measurements is adjusted to allow for non-ignorable missing data due to informative dropout, which cannot be appropriately handled by the standard linear mixed effects models alone. In addition, the joint model utilizes information from both outcomes, and could be substantially more efficient than the separate analysis of the competing risk survival data as shown in our simulation study. The performance of our method is evaluated and compared with separate analyses using both simulated data and a clinical trial for the scleroderma lung disease.
INTRODUCTION
In clinical trials and other follow-up studies, it is common that a response variable (e.g., a biomarker) is repeatedly measured during follow-up and the occurrence of some key event, which could cause non-ignorable missing data for the biomarker, is also monitored. Often, the occurrence of the event is censored by some competing risks such as disease related dropout.
A typical example is the Scleroderma Lung Study (SLS) [1] which has motivated this research.
The SLS is a double-blinded, randomized controlled study on 162 patients, with 81 in each group. The goal of the SLS is to evaluate the effectiveness of oral cyclophosphamide (CYC) versus placebo in the treatment of active, symptomatic lung disease due to scleroderma.
One outcome variable is forced vital capacity (FVC, as % predicted), a measure of lung function determined longitudinally at 3-month intervals. Another important measure is a clinical outcome variable -the time to treatment failure or death. Here a treatment failure occurs when %FVC of a patient in either group falls by ≥ 15% after 6 months in the study.
In addition, there are also considerable disease-related dropouts during the follow-up. Note that both death and dropout would cause non-ignorable missing data for the longitudinal measurements of %FVC.
Separate analysis for each of these endpoints has been studied extensively. For the time to event data, Cox's [2] proportional hazards model is popular, while mixed effects models and the GEE method are widely used for longitudinal measurements [3] [4] [5] [6] . However, joint analysis of both outcomes is often needed. This is the case for the SLS for two primary reasons. First, we are interested in evaluating the effects of CYC treatment on the two endpoints, %FVC and the time to treatment failure or death, simultaneously, since CYC is considered effective if it can either improve the %FVC of the patients in the study or lower the risk of treatment failure or death. Thus, it is necessary to build a more inclusive model which links the two aspects together. Secondly, the procedure of estimating the effects of CYC on the longitudinal outcome %FVC alone can be complicated by the disease-related dropout process or death, in which patients with worse scleroderma lung disease prognoses tend to withdraw from the study early or die, and hence are lost to follow up. Such non-ignorable missing data may lead to biased inferences if a separate analysis is performed on the longitudinal data using the mixed effects model or the GEE method [7, 8] .
Joint modeling of the two different types of endpoints simultaneously has received considerable attention in recent years [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] . A joint model enables one to evaluate effects of factors of interest on both endpoints at the same time [9, 10] , and also, it can be used to adjust inferences about longitudinal data for outcome-dependent missing values, of which the assumption of missing data mechanism can be non-ignorable non-response (NINR) [11, 12] .
In addition, we expect to gain more efficiency in statistical inferences with a joint model since information from both endpoints is utilized. A possible fourth advantage of joint modeling stems from other scientific investigations, especially AIDS studies, in which the interest is to characterize the relationship between the CD4 count and the time to AIDS. One common procedure is that the true underlying trajectory of the CD4 count can be first modeled, and then be incorporated into a Cox model for the time to AIDS [13, 14] , or an accelerated failure time model in other applications if the proportional hazards assumption fails for the survival endpoint [15] .
However, previous joint models only deal with a single failure type with noninformative censoring for the time to event, and thus are not applicable to survival data with competing risks or informative censoring. In our SLS data, disease-related dropout should be taken into account along with treatment failure or death in a joint analysis with %FVC for two reasons.
First, disease-related dropout is regarded as informative censoring for treatment failure or death, since it is recognized that both types of events are related to the patient disease condition. Secondly, disease-related dropout generates non-ignorable missing values in %FVC.
for more than one distinct failure type. Our model enables one to handle informative censoring by treating it as a competing risk. It also allows the non-ignorable missingness after event times. We adopt a linear mixed effects sub-model for the longitudinal measurements and a mixture sub-model for competing risks survival data which is similar to that of Larson and Dinse [20] and Ng and McLachlan [21] . The mixture model for competing risks enables one to evaluate the effects of some factors on both the marginal probabilities of occurrence of the risks and the conditional cause-specific hazards. One major difference of our mixture model from their approach is that we introduce subject-specific random terms which are linear in the random effects from the mixed effects sub-model for the longitudinal measurements. Therefore, conditional on common covariates, the correlation between the two endpoints is characterized by the latent random effects shared by the sub-models for longitudinal measurements and competing risks data, respectively. Another commonly used model for competing risks is the cause-specific hazards proposed by Prentice et al [22, 23] . Joint modeling of longitudinal data and competing risks using cause-specific hazards will be studied in a sequel paper. An EMbased algorithm is derived to estimate the parameters in both sub-models, and the inverse of the empirical Fisher information from the profile likelihood is used to approximate the variance-covariance matrix of the estimators. It is worth noting that the estimation procedure for joint analysis of longitudinal measurements and competing risks failure time data is more complicated than that for longitudinal measurements and survival data with a single failure type. With the two-step mixture sub-model for competing risks event times, we must introduce additional hidden variables to simplify the EM algorithm.
This article is organized as follows. The model and the estimation procedure are described in Section 2. In Section 3, a real data application is illustrated by the SLS clinical trial. In Section 4, the performance of the joint model is examined by simulation studies, and the joint model is compared to separate analyses in terms of the bias, the empirical standard error, the estimated standard error, and the power of the tests for some covariates. We also examined the estimates from the joint model with a single failure type in the presence of informative censoring. Some concluding remarks and possible future directions of our method are given in 
MODEL AND ESTIMATION

The joint model
Suppose there are n subjects in the study. Let Y i (t) be the measurement of a response variable fails from the kth type of failure, where k = 1, . . . , g. Throughout, the censoring mechanism is assumed to be noninformative. As stated before, informative censoring can be treated as one of the g types of failures. We also assume that each subject in the study will eventually fail from one of the g possible failure types.
Our joint model for Y (t) and C consists of the following three components
(1)
where we denote
The linear mixed effects model (1) is the sub-model for the longitudinal outcome Y i (t), and (2) and (3) specify the sub-models for the competing risks survival data with π k (X
i , W ki ; α) being the marginal probability of subject i failing from risk k, and λ k (t; X cause-specific hazard for risk k, also referred to as the component hazard [20, 21] , in which λ 0k (t) is a completely unspecified baseline hazard function for risk k, where k = 1, . . . , g.
In the sub-model (1), X
i (t) is a vector of covariates associated with the longitudinal trajectory Y i (t) and is allowed to change over time,X (1) i (t) may be the same as X (1) i (t) or just a subset of the elements in X (1) i (t), β 1 represents the fixed effects of X (1) i (t), U 0i is a random intercept, U 1i can be interpreted as subject-specific effects ofX for all t ≥ 0 is the measurement error. We assume that
and is independent of i (t). We further assume that i (t 1 ) is independent of i (t 2 ) for any
and V ki , and the V ki s are usually referred to as frailties in regression models for survival data. It is reasonable to assume that U i , W ki , and V ki from the same subject are correlated.
The simplest form is
with θ k and ν k being unknown parameters. We use this type of formulation in our joint model. Therefore, we need to rewrite
T and ν = (ν
The sub-model (2)- (3) 
i (t) are vectors of covariates associated with the marginal probability and the conditional cause-specific hazards, respectively. At last, we assume that the longitudinal measurements are independent of the competing risks survival data, conditional on all the covariates and random effects. Through (1)- (3), we adopt the most generic notation for the covariates which are used in different parts of the model. In practice, the vectors X 
i , and X (3) i (t) may have components in common. In the SLS data example as illustrated in Section 3, the three vectors are identical, containing the baseline %FVC, the degree of fibrosis in the lung, the treatment CYC, and an interaction between fibrosis and CYC.
We have the following remarks on our joint model. Remark 2. Our joint model proposed in this article belongs to the class of random-effects selection models, which assume the missing data in longitudinal measurements after dropout are non-ignorable [12] . This type of missing data in longitudinal measurements cannot be correctly analyzed using the usual linear mixed effects models that require the missing mechanism to be missing at random (MAR) when some assumptions are satisfied [24, 25] . [24] , missing completely at random (MCAR) occurs when
for all Y and φ, where φ is an unknown parameter. Missing at random
A missing mechanism is said to be ignorable if it is MCAR or MAR; and non-ignorable otherwise. In the study of longitudinal data with informative dropout, the time to dropout T has direct correspondence with M if there are no missing data before dropout. Under random-effects selection models, T is assumed to be independent of Y given random effects U [12] . Therefore,
Each density f here should be indexed by some unknown parameters which have been left out for simplicity. The above equation indicates that the conditional distribution of T given Y depends on both Y (o) and Y (m) , which indicates that the missing mechanism is non-ignorable.
However, for the missing data in longitudinal measurements before dropout, we need to assume the missing mechanism is MAR. If the informative dropout is one of the competing risk in the follow-up, and it is related to both the longitudinal outcome and the time to some event of interest, a competing risks framework should be considered. It is necessary to take into account the correlation between the informative dropout and the event of interest, and more importantly, to adjust the inference on longitudinal measurements for non-ignorable missing values after the informative dropout.
Parameter estimation
. . , λ 0g (t)) be the vector containing all the unknown parameters from (1)- (3). Suppose the longitudinal outcome Y i (t) is observed at time points t ij for j = 1, . . . , n i , and is denoted as
Note that the set (t i1 , . . . , t ini ) can be different among subjects, due to different dropout times and the fact that some patients may miss one or more visits. We assume that the missing values in the longitudinal measurements caused by reasons other than occurrence of events are missing at random. For example, a patient could remain in the study without showing up in some pre-specified visits. Recall that the competing risks endpoint on subject i is
It is important to note that the joint distribution of (Y, C) is completely determined by f (Y |U ), f (C|U ), and f (U ), which are specified in models (1)-(3). The full likelihood function for Ψ, conditional on the observed data
. . , n and the covariates, is thus
where the second equality follows from the assumption that Y and C are independent conditional on all the covariates and random effects. In the above expression, for a censored subject with censoring time T i , we have
Here, S k (t) and f k (t) are the conditional cause-specific survival and density functions for risk
To maximize the above likelihood, the cumulative baseline hazard functions are assumed to be step functions with jumps at observed event times. It is obvious the observed-data likelihood is difficult to maximize in the presence of integration. We may treat random effects U as missing data and use the EM algorithm to maximize the conditional likelihood in which the functions of U are replaced by their expectations given the observed data. However, for censored subjects, the term 
. , g. This is similar to what Ng and
McLachlan [21] postulated. Therefore the complete-data likelihood is
Copyright c It is clear that now the complete-data log-likelihood is linear in the components π k , f k , and S k , so that the parameters α and θ can be well separated from γ and ν.
The maximum likelihood estimate of Ψ is obtained via an EM-based algorithm, which involves iterations between an E-step and an M-step. In the E-step of the (m + 1)th iteration, we need to evaluate the expectation of the complete-data log-likelihood conditional on the observed data (Y, C) and the current parameter estimate, say Ψ (m) . This is equivalent to calculating the expected values of all the functions of U and τ that appear in the completedata log-likelihood. We write l(Ψ; U, τ ) = logL(Ψ; Y, C, U, τ ) with L as defined in (7), where we drop Y and C to simplify the notation. We have
The second equality holds because l(Ψ; U, τ ) is a linear function of τ . Therefore, the only hidden
is U , and computation of the conditional expectation of complete-date log-likelihood is reduced to evaluating the expectation of all the functions of U ,
, and we can write
In the M-step,
is maximized with respect to Ψ, so that we can update the estimate of Ψ to get Ψ (m+1) . We write Q(Ψ;
Recall that Ψ = (β, Σ, σ 2 , α, θ, γ, ν, λ 01 (t), . . . , λ 0g (t)). In Appendix we show that β, Σ, σ 2 , and cumulative baseline hazard functions H 0k (t) can be updated with closed forms (30)- (33),
where H 0k (t) is a step function with jumps at observed event times due to risk k, k = 1, . . . , g. No closed-form solutions exist for α, θ, γ, and ν, which need to be updated using a one-step Newton-Raphson algorithm in each iteration as given in (38)-(49). Then Ψ (m+1) will be the input for the E-step in the next iteration. The algorithm stops when the convergence criteria are satisfied. The technical details of this EM-based algorithm are deferred to Appendix.
Standard error estimation
Louis [26] proposed a method for computing the observed information matrix together with the EM algorithm. However, this method is computationally unattractive and time-consuming for our model in which the nonparametric baseline hazards are involved. Here we develop a method similar to that of Lin, McCulloch and Rosenheck [27] . We split the parameter vector Ψ into two components, the parametric component Ω = (β, Σ, σ 2 , α, θ, γ, ν) and the collection of 
Wald's tests can then be performed based on the estimated variance-covariance matrix. Finally, we mention that Zeng and Cai [10] proposed another method based on numerical differentiation of the profile likelihood which is computationally intensive. Our method is more efficient in computation. only given a partial dose, and the dose was gradually increased to the assigned level within the first 6 months. The treatment was given for 12 months from the baseline and thus the primary analysis has been based on the first 12 months data. In addition to treatment failure or death, there are considerable dropouts during the follow-up. Specifically, as summarized in Table 1 , we have observed the following: (1) 16 treatment failures or deaths; (2) 32 informative dropouts due to adverse event (AE), serious adverse event (SAE), or worsening disease; (3) 10 noninformative dropouts with no evidence showing that the dropouts were related to the disease. For example, the patient may have moved out of the city before completion of the study.
The informative dropout not only causes non-ignorable missing data in %FVC which indicates linear mixed effects models are not applicable, but also introduces informatively censored events for treatment failure or death. Therefore, we have to take into account this type of events when evaluating the treatment effects on %FVC outcome and the risk of treatment failure or death. Figure 1 shows the longitudinal profile of %FVC over time for the CYC group versus the placebo. We observe a large variation in the baseline %FVC. There is no apparent time trend for both groups. Figure 2 shows the average, the lower quartile, and the upper quartile of %FVC within each group at months 0, 3, 6, 9, and 12. These quantities were calculated on those who had not dropped out by the time. It is observed that the average %FVC initially decreases in the CYC group. One explanation may be that prior to month 6 patients were only given partial doses, not allowing sufficient time or dosing for the treatment to take effect. To account for this, we only used data from month 6 and thereafter in the subsequent analysis. There were 10 patients with follow up ≤ 3 months, so they were not included in the analysis.
The figure also shows that the CYC group tends to have a higher %FVC on average than the placebo group from month 9. However, no significant between-group difference is identified by the t-test at each visit (results not shown), and the figure indicates that the two groups have about the same interquartile ranges. We should note that both curves could be biased due to non-ignorable missing data in %FVC. Since patients with lower %FVC are more likely to dropout due to AE, SAE, worsening disease, or death, the observed curves for %FVC would be higher than the true population mean.
For illustrative purposes, we considered two confounding factors in our model when assessing the CYC treatment effects: the baseline %FVC and the degree of fibrosis in the lung. These elements were stated for the primary analysis in the recorded manual of operations. No statistical selection procedure was used. We also considered the interaction between treatment CYC and fibrosis, which was indicated to be significant for %FVC measurements in preliminary analyses. Thus, we applied the joint model to the SLS data with 3 covariates: baseline %FVC, fibrosis, and the treatment group indicator, as well as the interaction between CYC and fibrosis.
In the sub-model for %FVC, we fitted a linear mixed effects model with a random intercept and fixed effects for the 3 factors along with the interaction between CYC and fibrosis, and these were also incorporated in the mixture sub-model for the competing risks event times.
Two competing risks, treatment failure or death and disease-related dropout, were analyzed together with %FVC using the following joint model. In the sub-model for %FVC, we assume, for subject i at visit j,
where F V C 0i is the baseline %FVC, F IB i is the degree of fibrosis in the lung, CY C i is 1 or 0 as a group indicator for the CYC treatment or placebo, U i is the random intercept with a mean zero normal distribution, and the ij 's are the mutually independent measurement errors. For the competing risks survival data, we formulate the probability of treatment failure or death by the following:
and the conditional cause-specific hazards for treatment failure or death (risk 1) and diseaserelated dropout (risk 2) are specified as
= λ 01 (t)exp{γ
respectively.
The results of such a joint analysis are summarized in Table 2 , together with those from a linear random intercept model for the longitudinal outcome %FVC alone. In the joint analysis, the interaction between CYC treatment and fibrosis is 1.79 with p-value 0.006, which suggests that the treatment CYC is more effective for the patient with a higher degree of fibrosis in the lung. However, the linear mixed effects model for %FVC alone failed to detect this effect.
The test for the overall effects of treatment CYC can be done by jointly testing the two terms, the main effect and the interaction with fibrosis. The test gives p-value < 0.0001 and 0.13 in the joint model and the separate analysis, respectively. In the joint model the inference for the effect of CYC has been adjusted for the nonignorable missing data in %FVC, but we fail 
SIMULATION STUDY
We examined the finite sample performance of our joint model and the proposed estimation procedure using simulated data. We primarily looked at three aspects: first, we investigated for the joint model the simulated coverage probability of the 95% confidence intervals which were obtained based on the estimated standard errors using the method described in Section 2.3;
second, the joint model was compared to the separate analysis of either the longitudinal data or the competing risks survival data in terms of the bias, the empirical standard error, the estimated standard error, and the power of the tests for the effects of some factors; third, we examined the parameter estimates from a joint model with a single failure type in the presence of informative censoring, and the results were compared to our joint model which treated the informative censoring as a competing risk.
The longitudinal measurements were simulated from the following random intercept model
where the covariates X 1i ∼ N (2, 1.0) and X 2i ∼ Bernoulli(0.5) with X 2 acting as a treatment group indicator in randomized trials. The random intercept U i ∼ N (0, 0.1) is independent from the measurement error ij ∼ N (0, 0.25). We simulated two competing risks for event times, say risk 1 and risk 2, with the marginal probability for risk 1 specified as and the following conditional hazards for the two risks:
with baseline hazards held constant at 0.1 and 0.2 for risk 1 and 2, respectively, so that the time to each risk forms an exponential distribution. The censoring time is set to exp(10) to obtain average censoring rate at about 20%, the events of risk 1 at about 60%, and the events of risk 2 at about 20%. The longitudinal outcome was missing after the observed or censored event times. Table 3 shows the simulated coverage probability of the 95% confidence intervals from such a joint model at two sample sizes, 100 and 500, with 200 Monte Carlo samples for each. In the table we write σ 2 u for the variance of the random intercept U i . It is shown that the simulated coverage probability of confidence intervals is close to the nominal value 0.95.
Next we compared the joint model to the separate analysis of either endpoint on the following items: the bias of the point estimates, the empirical standard error, the estimated standard error, and the mean square error. We simulated the longitudinal outcome from a random slope linear model
where X 2i has the same distribution as in (16)- (19) , and the random slope U i ∼ N (0, 0.5).
The time span between two adjacent visits is 0.5. Two competing risks were simulated using model (17)-(19) but the random effect U i was from (20) this time. The Monte Carlo samples were analyzed in two ways: the joint model as specified in (17)- (20), and the separate analysis of the two endpoints. The separate analysis was done by fitting a random slope linear model (20) for the longitudinal outcome and a mixture model for the competing risks failure time data with random effectŨ i as follows: 
whereŨ i is assumed to be a zero-mean Gaussian random variable with varianceσ 2 u . It is worth noting that for the separate competing risks model (21)- (23), there is no longer a coefficient θ 1 for the random effectŨ i in (21) to ensure identifiability. It is easy to see thatσ (18)- (19) of the joint model. In this simulation, θ 1 is set to 1,
We used a similar approach as proposed in Section 2.3 to compute the variance-covariance matrix for the parameters in (21)-(23). The simulation was based on 200 Monte Carlo samples, and two sample sizes were considered (Table 4A and   Table 4B ). We label the empirical standard error as SE, the median of estimated standard error as Est.SE, and the mean square error as M SE S and M SE J for the joint model and the separate analysis, respectively.
The results can be summarized as follows. First of all, the time trend β 1 of the longitudinal measurements is severely underestimated in the separate analysis, even for a large sample size (say, 500). The variance of the time trend, σ 2 u , is also negatively biased. This is the consequence of the informative dropout process in which for positive coefficients ν 1 and ν 2 , we observe a higher risk of dropout for those subjects with greater than average increasing rates over time in the longitudinal outcome. The resultant non-ignorable missing values after dropout cannot be accounted for in the linear mixed effects model alone and thus biases in the estimated time trend and its variance are observed. However, we are able to obtain almost unbiased estimates for these quantities in the joint analysis, where the informative dropout process has been modeled together with the longitudinal measurements. Our results are consistent with the findings of Henderson, Diggle, and Dobson [9] . Second, it is observed that the joint model provides much more accurate estimates for ν 1 and ν 2 , the coefficients of the random effect in the hazards, than those from the mixture model alone which produces even worse estimates when the sample size is not that large (say, 200). Given that the separate analysis of the simulated competing risks survival data using the mixture model (21)- (23) is correct, this finding indicates that we can improve the efficiency of frailty estimation in the survival endpoint by combining the information of the longitudinal outcome, if the latter is correlated with the frailty and the correlation is correctly modeled. Third, in the separate analysis for the competing risks survival data, the standard errors are overestimated for almost all the parameters compared to the empirical ones, especially for ν 2 which is the coefficient of the random effect for failure type 2. In contrast, we can obtain more accurate standard error estimates from the joint model.
We observed similar results from the analysis based on the joint model (16) IV, respectively. It is shown that the analysis for competing risks alone has much lower power than the joint model in Models II, III, and IV for almost all sample sizes. This is as expected from our simulation results in Tables 4A and 4B , where we observe inflated variance estimates for the competing risks failure time data in the separate analysis, which, in turn, result in the loss of power for the tests.
We also examined the behavior of the joint analysis of longitudinal measurements and survival data with a single failure type in the presence of informative censoring. The Monte Carlo samples were generated from the joint model (17)- (20), and were analyzed by both the correct method and the following joint model in which risk 1 is the event of interest:
Here, failures due to risk 2 were treated as noninformatively censored events. Table 6A Our method can also be extended to robust inference for joint analysis of longitudinal measurements and survival data to handle outlying observations in the longitudinal outcome.
One possible approach is to use the idea of Richardson [29] by incorporating weight functions in maximum likelihood and restricted maximum likelihood estimating equations. Another option is to replace the normal distribution assumption for measurement errors with the t distribution to take into account longer-than-normal tails [30, 31] . We also know that in the scleroderma study influential points and outliers plausibly occur.
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APPENDIX
The EM-based Algorithm E-step:
Because the complete-data log-likelihood is linear in τ , we can write
, where m indicates that the parameter estimates are from the mth iteration of the EM algorithm. In the E-step of the (m+1)th iteration, for the censored subject i, we have
which is a function of the hidden variable U . Therefore, we need to evaluate the expected Prepared using simauth.cls data and the current parameter estimates. We have
where we use the fact
The distribution of U |Y, Ψ (m) is multivariate normal with an easily derived mean and variance covariance matrix, and
The integrals can be evaluated using Gauss-Hermite quadrature [32] .
M-step:
The vector of parameters Ψ is updated by maximizing Q(Ψ;
In the formula below, we use E to stand for E U,τ |Y,C,Ψ (m) . Closed-form estimates are available for β, Σ, σ 2 , and baseline hazards λ 0k (t) for k = 1, . . . , g, whose cumulative function H 0k (t) is shown below. We write vector X
T and have
(1) 
and
In calculation of the baseline hazards, the failure time observations are firstly ordered from the smallest to the largest. 
for q = 1, . . . , q k .
No closed-form solutions exist for α, θ, γ, and ν. They satisfy the following score equations, respectively: 
for k = 1, . . . , g. We do not need to solve the above equations, and the parameters α, θ, γ, and ν can be updated using the following one-step Newton-Raphson algorithm in each iteration. the expectation-conditional maximization (ECM) algorithm [33] . By the ECM algorithm, the maximization procedure is much simplified conditional on some parameters being estimated, due to the difficulty of maximizing the likelihood with respect to α, θ, γ, and ν simultaneously in our joint model formulation. In addition, it is shown that the ECM algorithm has the same convergence features as the EM algorithm.
Figures and Tables Note: In the separate analysis, we used the linear mixed effects model (20) for longitudinal data and the mixture model (21)-(23) for competing risks survival data, respectively. The joint analysis is based on model (17)- (20) . Note: The joint analysis with competing risks survival data is based on the model (17)- (20), and the joint analysis with a single failure type is based on the model (24)- (25). 
